APT Therapeutics Says EPO to Grant Patent Covering Site-specific Protein Modification | GenomeWeb

This story originally ran on March 2.

Advanced Proteome Therapeutics said this week that the European Patent Office "intends" to grant a patent covering the company's method for site-specifically modifying proteins.

According to a statement from APT, site-specific modifications are often necessary to prepare proteins for commercial use, and the method developed by the company is for discovering novel protein sites for attaching entities to enhance the properties of proteins.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.